keyword
MENU ▼
Read by QxMD icon Read
search

Treatment Complication In Pediatric Leukemia

keyword
https://read.qxmd.com/read/30862935/altered-proteome-of-high-density-lipoproteins-from-paediatric-acute-lymphoblastic-leukemia-survivors
#1
Maryse Fournier, Eric Bonneil, Carole Garofalo, Guy Grimard, Caroline Laverdière, Maja Krajinovic, Simon Drouin, Daniel Sinnett, Valérie Marcil, Emile Levy
Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children. With the use of more modern, efficient treatments, 5-year survival has reached more than 90% in this population. However, this achievement comes with many secondary and long-term effects since more than 65% of the survivors experience at least one severe complication, including the metabolic syndrome and cardiovascular diseases. The main objective of the present work was to characterize the composition of HDL particles isolated from pediatric ALL survivors...
March 12, 2019: Scientific Reports
https://read.qxmd.com/read/30849003/decreased-early-mortality-in-young-adult-patients-with-acute-lymphoblastic-leukemia-treated-at-specialized-cancer-centers-in-california
#2
Elysia M Alvarez, Marcio Malogolowkin, Qian Li, Ann Brunson, Brad H Pollock, Lori Muffly, Ted Wun, Theresa H M Keegan
PURPOSE: Studies suggest that patients with acute lymphoblastic leukemia (ALL) have superior survival when treated at specialized cancer centers (SCCs). However, the association of early mortality (< 60 days) with location of initial care, sociodemographic factors, and complications has not been evaluated in pediatric and young adult (YA) patients with ALL. METHODS: Using the California Cancer Registry linked to hospitalization data, we identified pediatric and YA patients with ALL who received inpatient leukemia treatment between 1991 and 2014...
March 8, 2019: Journal of Oncology Practice
https://read.qxmd.com/read/30848067/use-of-granulocyte-colony-stimulating-factor-and-risk-of-relapse-in-pediatric-patients-treated-for-acute-myeloid-leukemia-according-to-nopho-aml-2004-and-db-aml-01
#3
Ditte J A Løhmann, Peter H Asdahl, Jonas Abrahamsson, Shau-Yin Ha, Ólafur G Jónsson, Gertjan J L Kaspers, Minna Koskenvuo, Birgitte Lausen, Barbara De Moerloose, Josefine Palle, Bernward Zeller, Henrik Hasle
BACKGROUND: Supportive-care use of granulocyte colony-stimulating factor (G-CSF) in pediatric acute myeloid leukemia (AML) remains controversial due to a theoretical increased risk of relapse and limited impact on neutropenic complications. We describe the use of G-CSF in patients treated according to NOPHO-AML 2004 and DB AML-01 and investigated associations with relapse. PROCEDURE: Patients diagnosed with de novo AML completing the first week of therapy and not treated with hematopoietic stem cell transplantation in the first complete remission were included (n = 367)...
March 7, 2019: Pediatric Blood & Cancer
https://read.qxmd.com/read/30842156/osteonecrosis-in-children-and-adolescents-with-acute-lymphoblastic-leukemia-early-diagnosis-and-new-treatment-strategies
#4
Giada Biddeci, Gerardo Bosco, Elena Varotto, Marco Corradin, Giulia Geranio, Gloria Tridello, Marta Pillon, Elisa Carraro, Giacomo Garetto, Roya Assadi, Cosimo Gigante, Maria Caterina Putti
BACKGROUND/AIM: In the last few decades, treatment strategies for acute lymphoblastic leukemia (ALL) have been associated not only with improvement of prognosis, but also with an increasing rate of late complication as osteonecrosis (ON). Herein, the cumulative incidence, risk factors, new conservative therapeutic strategies as hyperbaric oxygen therapy (HBO), and outcome of symptomatic ON were studied in pediatric patients with ALL. PATIENTS AND METHODS: Between 2000 and 2017, 495 children and young adolescents with a diagnosis of ALL were evaluated...
March 2019: Anticancer Research
https://read.qxmd.com/read/30838178/infectious-complications-are-associated-with-alterations-in-the-gut-microbiome-in-pediatric-patients-with-acute-lymphoblastic-leukemia
#5
Jacob T Nearing, Jessica Connors, Scott Whitehouse, Johan Van Limbergen, Tamara Macdonald, Ketan Kulkarni, Morgan G I Langille
Acute lymphoblastic leukemia is the most common pediatric cancer. Fortunately, survival rates exceed 90%, however, infectious complications remain a significant issue that can cause reductions in the quality of life and prognosis of patients. Recently, numerous studies have linked shifts in the gut microbiome composition to infection events in various hematological malignances including acute lymphoblastic leukemia (ALL). These studies have been limited to observing broad taxonomic changes using 16S rRNA gene profiling, while missing possible differences within microbial functions encoded by individual species...
2019: Frontiers in Cellular and Infection Microbiology
https://read.qxmd.com/read/30823954/pediatric-malignant-mediastinal-masses
#6
Rahat-Ul-Ain Kashif, Mahwish Faizan, Saadia Anwar
OBJECTIVE: To describe the clinical spectrum and outcome-associated variables of pediatric malignant mediastinal masses in a resource-limited setting. STUDY DESIGN: Descriptive study. PLACE AND DURATION OF STUDY: Department of Pediatric Hematology-Oncology, The Children's Hospital, Lahore, from October 2016 to November 2017. METHODOLOGY: Children with malignant mediastinal masses were enrolled. The variables studied were median age at presentation, gender distribution, immunisation status, socio-economic background, causes of delayed presentation, presenting complaints, complications of disease, methods for mass biopsy, final diagnosis, staging, and outcome of the disease...
March 2019: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://read.qxmd.com/read/30774019/incidence-of-infections-after-therapy-completion-in-children-with-acute-lymphoblastic-leukemia-or-acute-myeloid-leukemia-a-systematic-review-of-the-literature
#7
Marie-Claude Pelland-Marcotte, Jeremiah Hwee, Jason D Pole, Paul C Nathan, Lillian Sung
Infections are a common complication of treatment for pediatric acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Less is known about infections occurring after treatment. We performed a systematic review of the literature to assess the incidence of infections after therapy completion in children and young adults with ALL or AML. Twenty-eight studies, with 4138 patients, were included. Four studies reported infections in patients who did not undergo hematopoietic stem cell transplant (HSCT)...
February 18, 2019: Leukemia & Lymphoma
https://read.qxmd.com/read/30657465/validation-of-an-instrument-to-measure-the-quality-of-life-in-children-with-oropharyngeal-mucositis-undergoing-cancer-treatment
#8
Rosaura Gutiérrez-Vargas, Eduardo Velasco-Rojano, Miguel Á Villasís-Keever, Javier Portilla-Robertson, Araceli Gutiérrez-Rodelo, Sonny Flores-Navarro, Luis E Juárez-Villegas, Marta Zapata-Tarrés
Background: Oropharyngeal mucositis (OM) is one of the primary complications arising during oncological treatment, which significantly reduces the patient's quality of life (QoL). The aim of this study was to translate, culturally adapt, and validate the use of a new Spanish version of the Oropharyngeal Mucositis-Specific Quality-of-Life instrument (OMQoL) for pediatric patients. Methods: A multicentric, cross-sectional validation study was conducted to translate and adapt OMQoL from English to Spanish for its use by children with OM aged 8-16 years...
2019: Boletín Médico del Hospital Infantil de México
https://read.qxmd.com/read/30431247/-bone-disorders-and-complications-of-pediatric-acute-lymphoblastic-leukemia-monocentric-study-and-review-of-the-literature
#9
REVIEW
L Pécheux, P Forget, C Geurten, L Rausin, R Nicolescu, C Hoyoux
Bone pain associated with bone marrow infiltration is often present at diagnosis of pediatric acute lymphoblastic leukemia (ALL). It sometimes signs the presence of pathological fracture, lytic lesions, arthritis, or osteitis associated to ALL that can delay the diagnosis. During treatment, bone complications (pain, osteopenia, fracture, avascular necrosis, ...) are also reported. In order to describe bone involvement (BI) of pediatric LLA, we reviewed the records of 104 patients followed in our unit. The overall incidence of BI was 67 %...
November 2018: Revue Médicale de Liège
https://read.qxmd.com/read/30427164/diabetic-ketoacidosis-following-peg-asparaginase-therapy
#10
Miriam Hinaa Ahmad, Ismat Shafiq
We report a case of a 21-year-old African American female with history of pre-diabetes, and a diagnosis of a rare leukemia, blastic-plasmacytoid dendritic neoplasm (BPDCN), who developed diabetic ketoacidosis (DKA) after the third dose of PEG-asparaginase infusion. She was successfully treated with insulin. Asparaginase is a vital part of treatment protocols for acute lymphoblastic leukemia (ALL) in combination with other chemotherapeutic drugs. Asparaginase therapy has been reported to cause hyperglycemia especially when used in conjunction with glucocorticoids for the treatment of ALL in the pediatric population...
October 31, 2018: Endocrinology, Diabetes & Metabolism Case Reports
https://read.qxmd.com/read/30408007/risk-factors-for-invasive-fungal-infection-in-children-and-adolescents-with-hematologic-and-malignant-diseases-a-10-year-analysis-in-a-single-institute-in-japan
#11
Ryoji Kobayashi, Daiki Hori, Hirozumi Sano, Daisuke Suzuki, Kenji Kishimoto, Kunihiko Kobayashi
Infection, especially invasive fungal infection (IFI), is an important complication of chemotherapy and stem cell transplantation. It is also a well-known risk factor in pediatric hematologic malignancy, acute myelogenous leukemia, recurrent disease and allogeneic stem cell transplantation. We previously revealed that a diagnosis of acute myelogenous leukemia, recurrent disease and >10 years of age were risk factors for IFI in patients with pediatric hematologic malignancies. We examined and compared the incidence, risk factors and mortality rate from IFI between 276 patients from 2007 to 2016 and patients in our past report...
December 2018: Pediatric Infectious Disease Journal
https://read.qxmd.com/read/30271006/successful-treatment-of-renal-infiltration-complicated-by-atypical-hemolytic-uremic-syndrome-in-a-leukemic-child
#12
Ö E Özmen, N Alici, B Topuz, M Akgül, E Akkuzu, Ö Akdemir, N Buyan, S Göral, Z Kaya
Renal infiltration in children with acute leukemia has been reported previously; however, it has rarely been described in association with atypical hemolytic uremic syndrome (aHUS). We present a case of 9-year-old boy who developed life-threatening aHUS in the 1st week of Burkitt leukemia/lymphoma diagnosis with renal infiltration. Complete resolution of aHUS was achieved after therapeutic plasma exchange. This is an uncommon complication of Burkitt leukemia/lymphoma in a pediatric case.
September 2018: Indian Journal of Nephrology
https://read.qxmd.com/read/30269037/pharmacogenomics-and-variations-in-the-risk-of-toxicity-during-the-consolidation-maintenance-phases-of-the-treatment-of-pediatric-b-cell-leukemia-patients-from-an-admixed-population-in-the-brazilian-amazon
#13
Darlen Cardoso de Carvalho, Alayde Vieira Wanderley, André Mauricio Ribeiro Dos Santos, Marianne Rodrigues Fernandes, Amanda de Nazaré Cohen Lima de Castro, Luciana Pereira Colares Leitão, João Augusto Nunes de Carvalho, Tatiane Piedade de Souza, André Salim Khayat, Sidney Emanuel Batista Dos Santos, Paulo Pimentel de Assumpção, Ney Pereira Carneiro Dos Santos
The treatment of Acute Lymphoblastic Leukemia (ALL) in children has a high clinical success rate, although toxicological complications are frequent, and often result in the interruption of the treatment. Various studies have shown that toxicities resulting from the treatment are influenced by pharmacogenetic variants. Most of this research has focused on relatively homogeneous populations, and the influence of these variants in highly admixed populations, such as that of Brazil, is still poorly understood. The present study investigated the association between pharmacogenetic variants and severe toxicities in pediatric B-cell ALL patients from an admixed population of the Brazilian Amazon...
September 15, 2018: Leukemia Research
https://read.qxmd.com/read/30231350/the-landscape-of-car-t-cells-beyond-acute-lymphoblastic-leukemia-for-pediatric-solid-tumors
#14
REVIEW
Christopher DeRenzo, Giedre Krenciute, Stephen Gottschalk
Adoptive cell therapy with genetically modified T cells holds the promise to improve outcomes for children with recurrent/refractory solid tumors and has the potential to reduce treatment complications for all patients. Although T cells that express chimeric antigen receptors (CARs) specific for CD19 have had remarkable success for B-cell-derived malignancies, which has led to their approval by the U.S. Food and Drug Administration, CAR T cells have been less effective for solid tumors and brain tumors. Lack of efficacy is most likely multifactorial, but heterogeneous antigen expression; limited migration of T cells to tumor sites; and the immunosuppressive, hostile tumor microenvironment have emerged as major roadblocks that must be addressed...
May 23, 2018: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/30139453/a-study-of-the-use-of-peripherally-inserted-central-catheters-in-cancer-patients-a-single-center-experience
#15
Irappa Madabhavi, Apurva Patel, Malay Sarkar, Pritam Kataria, Nagaveni Kadakol, Asha Anand
Effective and reliable venous access is one of the cornerstones of modern medical therapy in oncology. The focus of this prospective observational research is to study the various indications of a peripherally inserted central catheter (PICC) in different solid and hematological malignancies and the various complications and outcomes in the pediatric and adult cancer patients. This study was conducted in a prospective observational study design and collected data of patients with a diagnosis of any cancer, at a tertiary care oncology hospital in Ahmadabad, Gujarat, India, during a 2-year period...
September 2018: Journal of Vascular Nursing: Official Publication of the Society for Peripheral Vascular Nursing
https://read.qxmd.com/read/30027379/adjunctive-interferon-%C3%AE-immunotherapy-in-a-pediatric-case-of-aspergillus-terreus-infection
#16
Eemke L Assendorp, Mark S Gresnigt, Evelien G G Sprenkeler, Jacques F Meis, Natasja Dors, Jan W M van der Linden, Stefanie S V Henriet
Aspergillus terreus causes invasive aspergillosis (IA) in immunocompromised patients. Treatment is complicated by intrinsic resistance to amphotericin B and thereby contributing to a high mortality. Therefore, we conducted in vitro studies to investigate the effectivity of adjunctive recombinant interferon-γ immunotherapy. We describe a pediatric patient with A. terreus IA who received adjunctive recombinant interferon-γ (rIFNγ) immunotherapy. In vitro studies were conducted to investigate the capacity of rIFNγ to improve antifungal host defense in terms of fungal killing ability and the release of pro-inflammatory cytokines in cells of the patient as well as healthy controls...
October 2018: European Journal of Clinical Microbiology & Infectious Diseases
https://read.qxmd.com/read/30008805/an-uncommon-t-9-11-p24-q22-with-monoallelic-loss-of-atm-and-kmt2a-genes-in-a-child-with-myelodysplastic-syndrome-acute-myeloid-leukemia-who-evolved-from-fanconi-anemia
#17
Viviane Lamim Lovatel, Daiane Corrêa de Souza, Tatiana Fonseca Alvarenga, Roberto R Capela de Matos, Claudia Diniz, Marcia Trindade Schramm, Juan Clinton Llerena Júnior, Maria Luiza Macedo Silva, Eliana Abdelhay, Teresa de Souza Fernandez
Background: Myelodysplastic syndrome (MDS) is rare in the pediatric age group and it may be associated with inheritable bone marrow failure (BMF) such as Fanconi anemia (FA). FA is a rare multi-system genetic disorder, characterized by congenital malformations and progressive BMF. Patients with FA usually present chromosomal aberrations when evolving to MDS or acute myeloid leukemia (AML). Thus, the cytogenetic studies in the bone marrow (BM) of these patients have an important role in the therapeutic decision, mainly in the indication for hematopoietic stem cell transplantation (HSCT)...
2018: Molecular Cytogenetics
https://read.qxmd.com/read/30005182/factors-associated-with-a-prolonged-hospital-stay-during-induction-chemotherapy-in-newly-diagnosed-high-risk-pediatric-acute-lymphoblastic-leukemia
#18
Kasper Warrick, Sandra K Althouse, April Rahrig, Joy Rupenthal, Sandeep Batra
BACKGROUND: High Risk (HR) or Very High Risk (VHR) acute lymphoblastic leukemia (ALL) treated with 4 drug induction chemotherapy is often associated with adverse events. The aim of this study was to identify risk factors associated with a prolonged inpatient length of stay LOS during induction chemotherapy. PROCEDURE: Data from patients (N = 73) (age<21 years) was collected through a retrospective chart review. Univariable and multivariable logistic regression was used to test for statistical significance...
August 2018: Leukemia Research
https://read.qxmd.com/read/29988797/perforated-jejunitis-in-a-child-with-acute-lymphoblastic-leukemia-treated-with-pegaspargase
#19
Elizabeth R Tang, Teresa Chapman, Laura S Finn, Kasey J Leger
Survival rates of children with acute lymphoblastic leukemia have improved since the incorporation of asparaginase in the treatment protocol, but the medication has potential serious complications, including vascular thrombosis. Here, we describe the case of a 13-year-old boy with pre-T-cell acute lymphoblastic leukemia whose treatment course was complicated by perforated jejunitis requiring resection of a portion of his small bowel. Pathologic assessment showed transmural ischemia, mesenteric venous and arterial thrombi, and scattered cytomegalovirus inclusion bodies...
June 2018: Radiology Case Reports
https://read.qxmd.com/read/29925908/front-line-imatinib-treatment-in-children-and-adolescents-with-chronic-myeloid-leukemia-results-from-a-phase-iii-trial
#20
Meinolf Suttorp, Philipp Schulze, Ingmar Glauche, Gudrun Göhring, Nils von Neuhoff, Markus Metzler, Petr Sedlacek, Eveline S J M de Bont, Adriana Balduzzi, Birgitte Lausen, Olga Aleinikova, Sabina Sufliarska, Günter Henze, Gabriele Strauss, Angelika Eggert, Bernhard Kremens, Andreas H Groll, Frank Berthold, Christoph Klein, Ute Groß-Wieltsch, Karl Walter Sykora, Arndt Borkhardt, Andreas E Kulozik, Martin Schrappe, Christina Nowasz, Manuela Krumbholz, Josephine T Tauer, Alexander Claviez, Jochen Harbott, Hans H Kreipe, Brigitte Schlegelberger, Christian Thiede
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m2 , respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94...
July 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
keyword
keyword
161190
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"